BioVectra Revenue and Competitors

Claim your profile

Charlottetown , CAN



Total Funding



Estimated Revenue & Valuation

  • BioVectra's estimated annual revenue is currently $75M per year.(i)
  • BioVectra's estimated revenue per employee is $155,000

Employee Data

  • BioVectra has 484 Employees.(i)
  • BioVectra grew their employee count by 12% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation

BioVectra manufactures ingredients for global pharmaceutical and biotechnology clients offering therapeutics used in the treatment of cancer, kidney disease, cardio-vascular disease, multiple sclerosis, and many other serious diseases. With over 40 years experience, our company is proficient in synthetic organic chemistry, fermentation of chemical and biologic molecules, downstream processing, MPEG production and conjugation chemistry. We have submitted 10 product filings, including ANDA, DMF, VMF, and CMC section preparations for both the U.S. FDA and Health Canada. These filings have been made for both synthetic and biologic molecules, and include a human injectable API, as well as a final drug product. We operate from three, FDA-inspected facilities in Prince Edward Island, Canada, with the capacity to produce commercial-scale active pharmaceutical ingredients. Our operations are currently expanding to a fourth plant in Nova Scotia, offering further capacity for fermentation and small-scale complex chemistry. BioVectra has the experience and flexibility to work with small to large pharmaceutical, biotechnology, generic, and early stage companies. Our specialized capabilities, quality history, long-term customer relationships and culture of versatility all contribute to achieving our customers unique and diverse requirements.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





BioVectra News

2022-04-20 - DL-Dithiothreitol (DTT) Consumption Market Outlook 2022 ...

BioVectra; Suzhou Highfine; Hubei Kangbaotai; Hunan Yun Bang Biomedical; Zhangjiagang Xikai. Global market segmentation DL-Dithiothreitol (DTT) Consumption : DL...

2022-04-13 - BioVectra Breaks Ground On Expansion Of Charlottetown ...

BioVectra's mRNA Vaccine and Biomanufacturing Center will add 36,000 square feet to its existing Charlottetown campus and, when operational, the...

2022-04-06 - BIOVECTRA Starts Construction on its Charlottetown mRNA ...

BIOVECTRA is a global biotech and pharmaceutical CDMO (contract development and manufacturing organization) that specializes in clinical-to-...

2021-03-11 - PhaseBio Pharmaceuticals and BioVectra Enter into Supply Agreement to Support Development and Commercialization of Bentracimab

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--Mar 11, 2021-- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, and BioVectra Inc., an innovative global contract ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding